论文部分内容阅读
红细胞生成素(EPO)是一种糖蛋白,主要来源于肾脏。现在已能通过基因重组技术生产,从而可在临床上广泛应用。它主要作用于红系的BFU-E与CFU-F,并且通过其在幼红细胞膜上的受体而起到促进增生与分化的作用。1 如何选用EPO以及EPO对何种贫血的疗效比较好? ①肾功能衰竭时的贫血以EPO为首选药物。此时内生EPO的制造减少,不足以刺激造血,其他疗法不能代替;②EPO对多发性骨髓瘤(MM)、类风湿性关节炎以及其他恶性肿瘤性贫血的疗效也相当
Erythropoietin (EPO) is a glycoprotein mainly derived from the kidneys. Now it can be produced by genetic recombination technology, which can be widely used clinically. It acts primarily on erythroid-type BFU-E and CFU-F and acts to promote proliferation and differentiation through its receptor on the erythrocyte membrane. 1 how to choose EPO and EPO on the efficacy of which anemia is better? ① anemia in renal failure with EPO as the drug of choice. At this time the reduction of endogenous EPO manufacturing, not enough to stimulate hematopoiesis, other therapies can not be replaced; EPO on multiple myeloma (MM), rheumatoid arthritis and other malignant anemia effect is also quite